C79.11 is a specific ICD-10-CM code utilized for the clinical documentation of metastatic cancer that has spread to the kidney or renal pelvis from a primary site located elsewhere in the body. Unlike primary renal cell carcinoma (RCC), which originates within the renal parenchyma, secondary renal neoplasms are typically the result of hematogenous or lymphatic dissemination from distant organs. Common primary malignancies that metastasize to the kidneys include lung cancer, breast cancer, malignant melanoma, and gastrointestinal carcinomas. These secondary tumors are often multifocal and bilateral, and while they are frequently detected incidentally during staging workups for the primary disease, they can cause significant renal morbidity. In the context of the 2026 standards, this code is essential for distinguishing metastatic involvement from primary renal tumors, which significantly impacts treatment planning and prognostic assessment.
Distinguish between Primary and Secondary Malignancy
Example: Patient with known Stage IV Small Cell Lung Cancer (primary) presents with a new 2cm mass in the left renal cortex. Biopsy confirms metastatic lung carcinoma to the kidney. Assessment: Secondary malignant neoplasm of kidney and renal pelvis (C79.11). Primary site remains under active treatment with systemic carboplatin.
Billing Focus: Documentation must explicitly state the kidney involvement is metastatic or secondary. Coding C79.11 without identifying the primary site (if known) or using C80.1 if unknown can lead to claim denials.
Clarify the Primary Site of Origin
Example: Oncology follow-up for 68-year-old male with history of malignant melanoma of the right calf. Recent PET/CT shows increased uptake in the bilateral kidneys and renal pelvis. Renal biopsy consistent with metastatic melanoma. Plan: Initiate Nivolumab and Ipilimumab combination therapy.
Billing Focus: Identify both the secondary site (C79.11) and the primary site (e.g., C43.71). Sequence the code for the reason for the encounter first.
Document Current Status of Primary Neoplasm
Example: Evaluation of right renal pelvis mass in a patient with personal history of breast cancer (ER/PR+, HER2-). Biopsy indicates secondary malignant neoplasm of renal pelvis of mammary origin. Primary breast cancer was treated via mastectomy 5 years ago but is now considered recurrent/metastatic. Plan: Change hormonal therapy to Fulvestrant.
Billing Focus: If the primary site was previously excised but has recurred as metastasis, use the primary site code (e.g., C50.911) rather than a history code (Z85.3) if the patient is receiving active treatment for the metastatic spread.
Identify Complications and Symptoms Supporting Medical Necessity
Example: Patient with secondary malignant neoplasm of kidney from primary colon cancer presents with gross hematuria and severe right-sided flank pain. Imaging confirms the renal pelvic tumor is causing partial ureteral obstruction. Plan: Urgent ureteral stenting and palliative radiation.
Billing Focus: Documenting specific symptoms like hematuria (R31.9) or hydronephrosis (N13.30) provides medical necessity for procedures like stenting or specialized imaging.
Note Treatment Modality and Intent
Example: Metastatic renal pelvis tumor secondary to primary bladder cancer. Patient is currently on Cycle 3 of palliative chemotherapy. Physical exam shows new onset generalized weakness and cachexia. Assessment: Secondary renal malignancy (C79.11), Malignant cachexia (R64).
Billing Focus: Specifying whether the encounter is for chemotherapy (Z51.11) or symptom management (e.g., pain, cachexia) dictates the primary diagnosis sequencing for the visit.
Typically used for follow-up of metastatic disease involving multiple systems or requiring complex treatment decisions.
Appropriate for complex cases with high morbidity, such as cancer progression or severe treatment side effects.
Essential for confirming that a renal mass is a secondary metastasis rather than a primary tumor.
The standard imaging modality for staging and monitoring secondary renal neoplasms.
The core therapeutic procedure for patients with secondary renal malignancies.
Used to assess the renal pelvis and obtain retrograde pyelograms in cases of suspected secondary pelvic tumors.
Critical for the definitive diagnosis of a secondary vs. primary renal malignancy.
Often used as an initial screening tool or for guidance during needle procedures.
Used for palliative radiation therapy of symptomatic renal metastases.
Used for the initial consultation of a patient newly diagnosed with metastatic disease to the kidney.